Patient's Outcome Prognostic Factors
Conditions
Keywords
Autologous stem cell transplantation, rituximab, Follicular Lymphoma, prognosis
Brief summary
Introduction High dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT) is a therapeutic option in follicular Lymphoma after first line treatment failure. The clinical characteristics and outcome of FL patients who relapsed after HDT+ASCT and therapeutic management in the rituximab era are not well known and may represent a difficult challenge. Patients and Methods: The investigators conducted a retrospective analysis of FL patients who relapsed after HDT+ASCT in four French centers treated between 2000 and 2014. Clinical records were reviewed for clinical characteristics and treatment strategy at relapse. The investigators aimed to identify prognostic factors related to patient's outcome.
Interventions
None listed
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* they were older than 18 years * presented FL at diagnosis (Grade 1, 2, or 3a). * received high-dose therapy (HDT) with ASCT from 2000 to 2014
Exclusion criteria
1. they had already been treated with a 1st ASCT, 2. had a previous history of histological transformation before ASCT 3. if they were rituximab naive prior to ASCT.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survival after relapse (SAR) post ASCT in follicular lymphoma | Year 6 | Factors that predicted SAR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Histological Transformation at relapse | Year 6 | A biopsy was performed at the first relapse or progression after ASCT. |
| treatment of relapse | Year 6 | Chemotherapy, radiotherapy… |
Countries
France
Outcome results
None listed